ArticleTheScientificWorldJournal2026
Phytochemical Profiling and Neuropharmacological Evaluation of Baccaurea motleyana Bark Extract: In Vivo and In Silico Approaches.
Article in TheScientificWorldJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical Profiling and Neuropharmacological Evaluation of Baccaurea motleyana Bark Extract: In Vivo and In Silico Approaches.TheScientificWorldJournal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression, anxiety, insomnia, and muscle spasms are globally prevalent disorders. Although Baccaurea motleyana is traditionally used in folk medicine, its neuroprotective efficacy remains unexplored. This study evaluates the anxiolytic, antidepressant, sedative, and muscle relaxant properties of its bark methanol extract (BMB-ME) using in vivo and in silico analyses. Phytochemical analysis of BMB-ME was assessed by gas chromatography-mass spectrometry (GC-MS). Antidepressant activity was evaluated using the tail suspension test (TST) and forced swim test (FST), anxiolytic effects were assessed using the elevated plus maze (EPM) and hole board test (HBT), sedative effects were measured using the open field test (OFT) and hole cross test (HCT), and muscle relaxant activity was determined using the rotarod test. Moreover, molecular docking and ADMET analyses were performed. GC-MS of BMB-ME identified 38 compounds. It significantly reduced immobility in TST to 61.75 ± 1.87 s (p < 0.001) and in FST to 55.52 ± 3.14 s (p < 0.001) at 400 mg/kg. EPM results showed increased open arm time to 232.6 ± 7.24 s (p < 0.001), whereas OFT demonstrated reduced locomotion to 45.6 ± 1.92 (p < 0.001). Rotarod retention time decreased to 18.6 ± 0.99 s (p < 0.001), indicating muscle relaxation. Molecular docking showed favorable binding affinities for hexadecanoic acid and gamma-sitosterol (-8.3 to -8.1 kcal/mol), providing computational support. Overall, BMB-ME demonstrated preliminary antidepressant-, anxiolytic-, sedative-, and muscle relaxant-like effects in experimental models. Further studies are needed to isolate active compounds and clarify the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.